Unraveling the active conformation of urotensin II.

Urotensin II (U-II) is a disulfide-bridged undecapeptide recently identified as the ligand of an orphan G-protein-coupled receptor. Human U-II (H-Glu-Thr-Pro-Asp-cyclo[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH) has been described as the most potent vasoconstrictor compound identified to date. With the aim of elucidating the active conformation of hU-II, we have performed a spectroscopic analysis of hU-II minimal active fragment hU-II(4-11) in different environmental conditions. The analysis indicated that hU-II(4-11) was highly structured in the anisotropic membrane mimetic SDS solution, showing a type II' beta-turn structure, which is almost unprecedented for L-amino acid peptides. Micelle bound structure of hU-II(4-11) was then compared with those of four synthetic analogues recently synthesized in our lab, bearing modified Cys residues at position 5 and/or position 10 and characterized by different levels of agonist activity. The structures of the active compounds were found to be very similar to that of hU-II(4-11), while a barely active compound does not show any propensity to beta-turn formation. Furthermore, distances among putative pharmacophoric points in the structures of the active compounds obtained in SDS solution are in good agreement with those found in a recently described non-peptide agonist of the hU-II receptor. A type II' beta-turn structure was already found for the somatostatin analogue octreotide. On the basis of the similarity of the primary and 3D structures of U-II and somatostatin analogues and on the basis of the sequence homology between the GPR14/UT-II receptor and members of the somatostatin receptor family, a common evolutionary pathway for the signal transmission system activated by these peptide can be hypothesized.

[1]  K. Wüthrich NMR of proteins and nucleic acids , 1988 .

[2]  S. Awasthi,et al.  "Teflon-coated peptides": hexafluoroacetone trihydrate as a structure stabilizer for peptides. , 1997, Biopolymers.

[3]  Ethan S. Burstein,et al.  Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954). , 2002 .

[4]  D. Sargent,et al.  Membrane lipid phase as catalyst for peptide-receptor interactions. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Douglas,et al.  Human urotensin‐II is a potent spasmogen of primate airway smooth muscle , 2000, British journal of pharmacology.

[6]  G Vassart,et al.  Current developments in G-protein-coupled receptors. , 1991, Current opinion in cell biology.

[7]  M. Billeter,et al.  MOLMOL: a program for display and analysis of macromolecular structures. , 1996, Journal of molecular graphics.

[8]  S. Douglas,et al.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. , 2000, Trends in cardiovascular medicine.

[9]  V. Hruby,et al.  Relative conformational rigidity in oxytocin and (1-penicillamine)-oxytocin: a proposal for the relationship of conformational flexibility to peptide hormone agonism and antagonism. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Wüthrich,et al.  Torsion angle dynamics for NMR structure calculation with the new program DYANA. , 1997, Journal of molecular biology.

[11]  J. Thornton,et al.  PROMOTIF—A program to identify and analyze structural motifs in proteins , 1996, Protein science : a publication of the Protein Society.

[12]  P. Molenaar,et al.  Cardiostimulant effects of urotensin‐II in human heart in vitro , 2001, British journal of pharmacology.

[13]  H. Sarau,et al.  Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey , 2000, British journal of pharmacology.

[14]  H. Heng,et al.  Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. , 1995, Genomics.

[15]  S. Douglas,et al.  Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat , 2000, British journal of pharmacology.

[16]  Ettore Novellino,et al.  Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues. , 2002, Bioorganic & medicinal chemistry.

[17]  H. Dyson,et al.  Polypeptide backbone resonance assignments and secondary structure of Bacillus subtilis enzyme IIIglc determined by two-dimensional and three-dimensional heteronuclear NMR spectroscopy. , 1991, Biochemistry.

[18]  Richard R. Ernst,et al.  Multiple quantum filters for elucidating NMR coupling networks , 1982 .

[19]  E. Novellino,et al.  A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. , 2002, Journal of medicinal chemistry.

[20]  Ad Bax,et al.  MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy , 1985 .

[21]  K Wüthrich,et al.  The program XEASY for computer-supported NMR spectral analysis of biological macromolecules , 1995, Journal of biomolecular NMR.

[22]  Jilly F. Evans,et al.  Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. , 1999, Biochemical and biophysical research communications.

[23]  S. Douglas Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'? , 2003, Current opinion in pharmacology.

[24]  L. Moroder,et al.  Peptide hormone-membrane interactions. Intervesicular transfer of lipophilic gastrin derivatives to artificial membranes and their bioactivities. , 1993, Biochimica et biophysica acta.

[25]  A. Davenport,et al.  Is urotensin‐II the new endothelin? , 2002, British journal of pharmacology.

[26]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[27]  A. Hagler,et al.  Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Coy,et al.  Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists. , 2002, European journal of pharmacology.

[29]  Yumiko Saito,et al.  Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction , 1999, Nature Cell Biology.

[30]  H. Sarau,et al.  Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 , 1999, Nature.

[31]  T. Klabunde,et al.  Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. , 2002, Journal of medicinal chemistry.

[32]  C. Yu,et al.  NMR and dynamical simulated annealing studies on the solution conformation of urotensin II. , 1994, Biochimica et biophysica acta.

[33]  E. Novellino,et al.  Recent structure-activity studies of the peptide hormone urotensin-II, a potent vasoconstrictor. , 2004, Current medicinal chemistry.

[34]  Richard R. Ernst,et al.  Investigation of exchange processes by two‐dimensional NMR spectroscopy , 1979 .